Skip to content

Author

Munenobu Kashiwa

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer.

BACKGROUND AND OBJECTIVES Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are standard first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, yet the cost architecture across the full treatment trajectory remains poorly characterized....

Munenobu Kashiwa, Kensuke Moriwaki · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.